media – Page 539 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)

Bayer reported that the Chinese Food and Drug Administration (CFDA) approved Stivarga (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib) (Press release, Bayer, DEC 13, 2017, View Source [SID1234522618]).
- Source: 1stoncology
- 531
- March 20, 2018
HCC New Approvals Nexavar® Stivarga®
Adaptimmune’s GSK-partnered T cells trigger responses in solid tumor patients

Adaptimmune has seen partial responses in three of the first four myxoid/round cell liposarcoma (MRCLS) patients treated with its T cells. The early data raised hopes the GlaxoSmithKline-partnered drug will be effective in multiple types of solid tumor, sending Adaptimmune shares up nearly 20%.
- Source: Fiercebiotech
- 551
- March 20, 2018
Clinical Trials MRCLS solid tumor
Ionis Pharmaceuticals Partners With Akcea Therapeutics in a Potential $1.7 Billion Deal

In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases. After reviewing its options, Ionis has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. What makes this deal a bit unusual is that Akcea is a subsidiary of Ionis.
- Source: pharmalive
- 558
- March 20, 2018
Akcea-TTR-LRx GlaxoSmithKline Market Views
FDA Approves Hizentra® (Immune Globulin Subcutaneous 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
- Source: finance.yahoo
- 685
- March 20, 2018
CIDP FDA Hizentra® New Approvals
Study highlights how EHR data can pinpoint undiagnosed genetic diseases

A new study out of Vanderbilt University Medical Center found genetic data in electronic health records can be used to spot undiagnosed diseases.
- Source: MedCity News
- 595
- March 20, 2018
EHR healthcare technologies and innovations medtech Researches
Implantable sensor relays real-time personal health data to a cell phone

Personalized medicine is one step closer for consumers, thanks to tiny, implantable sensors that could give an early warning of a person's developing health problems, indicate the most effective type of exercise for an individual athlete, or even help triage wounded soldiers. That's the vision for a family of devices that scientists are now developing. They have begun marketing their first device in Europe and hope to win approval for this technology in the U.S.
- Source: TechExplore
- 550
- March 20, 2018
digital health healthcare technologies and innovations New Approvals
Paraplegic Rat Walks Again After Therapy

Using electrochemical stimulation and robot-assisted rehabilitation techniques, researchers restore walking ability in a paraplegic rat. The study reports reorganization of neural branching in the reticular formation leads to new connections and is key to motor skill recovery.
- Source: NeuroScience News
- 516
- March 20, 2018
rehabilitation Researches spinal cord
Blockchain medical device set to improve the delivery for babies born by C-section

NnBu Holdings has developed a blockchain medical device to help deliver healthy outcomes for babies born by C-section.
- Source: Open Access Government
- 658
- March 19, 2018
blockchain digital health Researches
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program (AAV-CLN1), an AAV-based gene therapy for the treatment of CLN1 disease (infantile and late infantile onset Batten disease).
- Source: Tmcnet
- 431
- March 19, 2018
CLN1 disease lysosomal storage New Approvals
Autism’s social deficits are reversed by an anti-cancer drug

Using an epigenetic mechanism, romidepsin restored gene expression and alleviated social deficits in animal models of autism
- Source: Sciencedaily
- 500
- March 19, 2018
autism Researches romidepsin

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.